MicroPort CardioFlow Medtech Corp. (2160) AI Stock Analysis

• Market Cap: HK$2.99B
• Dividend Yield: N/A
• Average Volume (3M): 8.07M
• Price to Earnings (P/E): 563.6
• Beta (1Y): 1.86
• Revenue Growth: -4.38%
• EPS Growth: N/A
• Country: HK
• Employees: 430
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 2,412,706,800
• 10 Day Avg. Volume: 7,535,058
• 30 Day Avg. Volume: 8,069,439
• PEG Ratio: 0.34
• Price to Book (P/B): 0.68
• Price to Sales (P/S): 4.13
• P/FCF Ratio: -5.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.50
• Price Target Upside: 19.05% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: HK$1.50 ▲(19.05% Upside)

The overall stock score is primarily influenced by financial performance and valuation concerns. Strong revenue growth and a solid equity base are overshadowed by persistent losses and cash flow challenges. The high P/E ratio suggests overvaluation, while technical indicators show mixed signals with a potential for long-term growth.

MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model

Company Description

MicroPort CardioFlow Medtech Corp. (2160) is a leading medical technology company specializing in the development and manufacturing of innovative cardiovascular devices and solutions. The company operates primarily in the healthcare sector, focusing on products that enhance the treatment and management of heart-related conditions. Its core offerings include advanced cardiac devices, minimally invasive surgical tools, and diagnostic equipment, aimed at improving patient outcomes and supporting healthcare professionals in their daily practices.

How the Company Makes Money

MicroPort CardioFlow Medtech Corp. generates revenue through the sale of its medical devices and technologies to hospitals, clinics, and healthcare providers. The company’s key revenue streams include direct sales of cardiovascular devices, such as stents and balloons, as well as maintenance and support services for its products. Additionally, it may engage in partnerships with healthcare organizations and distributors to expand its market reach and enhance product distribution. Strategic collaborations with research institutions and participation in clinical trials can also contribute to revenue through grants and funding, while ongoing investments in R&D help drive future innovations and sales growth.

MicroPort CardioFlow Medtech Corp. Financial Statement Overview

Summary

MicroPort CardioFlow Medtech Corp. shows strong revenue growth and a solid equity base. However, negative EBIT, net income, and ongoing cash flow challenges significantly impact profitability and operational efficiency.

Income Statement

MicroPort CardioFlow Medtech Corp. has shown substantial revenue growth over the years, with a revenue growth rate of 7.54% from 2023 to 2024. However, the company is struggling with profitability as indicated by negative EBIT and net income, resulting in negative EBIT and net profit margins. The gross profit margin improved slightly, showing a focus on cost management, but overall profitability remains a challenge.

Balance Sheet

The company's balance sheet is relatively strong with a high equity ratio of 81.74%, indicating a solid capital base. The debt-to-equity ratio is low at 0.04, reflecting minimal leverage and reduced financial risk. However, the return on equity remains negative, driven by sustained net losses, which undermines the overall financial health.

Cash Flow

The cash flow statement indicates significant operational challenges, with zero operating and free cash flow in the latest period. The absence of positive cash flows highlights ongoing operational inefficiencies. The company has shown improvements in reducing free cash flow deficits over the years, but cash flow management remains an area of concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	367.53M	361.56M	336.21M	251.03M	200.81M	103.93M
Gross Profit	253.91M	251.21M	229.93M	162.13M	118.70M	45.38M
EBITDA	-87.81M	-113.32M	-386.05M	-347.91M	-173.99M	-227.43M
Net Income	4.85M	-49.45M	-471.53M	-454.39M	-183.26M	-398.09M
Balance Sheet
Total Assets	2.67B	2.68B	2.58B	3.00B	3.36B	1.11B
Cash, Cash Equivalents and Short-Term Investments	1.32B	1.36B	1.07B	2.08B	2.42B	612.47M
Total Debt	279.62M	76.86M	70.48M	95.47M	125.64M	15.83M
Total Liabilities	450.55M	454.07M	242.25M	247.55M	265.52M	1.46B
Stockholders Equity	2.18B	2.19B	2.33B	2.75B	3.10B	-345.18M
Cash Flow
Free Cash Flow	-179.62M	-270.06M	-237.50M	-231.60M	-269.94M	-167.97M
Operating Cash Flow	-26.82M	-111.67M	-206.99M	-182.53M	-161.50M	-109.75M
Investing Cash Flow	-668.17M	-798.50M	-596.06M	-179.78M	-437.48M	-56.42M
Financing Cash Flow	-2.75M	-56.31M	-25.61M	-136.42M	2.23B	676.42M

MicroPort CardioFlow Medtech Corp. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Neutral. The current price of 1.26 is below the 20-day moving average (MA) of 1.35, below the 50-day MA of 1.41, and above the 200-day MA of 1.05, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 41.55 is Neutral, neither overbought nor oversold. The STOCH value of 4.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2160.

MicroPort CardioFlow Medtech Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	69 Neutral	HK$6.17B	19.27	11.24%	1.20%	25.18%	55.79%
1858	62 Neutral	HK$9.25B	33.51	5.55%	0.86%	-12.69%	-30.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2500	50 Neutral	HK$1.18B	―	-26.80%	―	-8.56%	-14.84%
2393	49 Neutral	HK$302.85M	0.31	-29.79%	―	6.10%	-115.12%
2160	49 Neutral	HK$2.99B	563.64	0.22%	―	-4.38%	―
9996	41 Neutral	€4.09B	―	-11.20%	―	29.25%	9.02%

MicroPort CardioFlow Medtech Corp. Corporate Events

MicroPort CardioFlow Expands with Major Acquisition in Cardiac Rhythm Management

MicroPort CardioFlow Medtech Corp. announced a significant acquisition involving the merger with a target company specializing in cardiac rhythm management. The transaction, valued at $680 million, will see the target company become an indirect subsidiary of MicroPort, enhancing its product platform and global market reach. This strategic move is expected to create synergies that will strengthen MicroPort’s position in the heart disease market by expanding its product pipeline and distribution capabilities.

The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.

MicroPort CardioFlow Reports Revenue Growth and Reduced Losses for H1 2025

MicroPort CardioFlow Medtech Corp. reported a 2.7% increase in revenue for the first half of 2025, driven by a substantial rise in overseas sales and the continued global commercialization of its key products. The company also significantly reduced its net loss to RMB2.2 million, down from RMB57.8 million in the same period of 2024, due to improved operational efficiency and a gain from the deemed disposal of an equity interest in an associate.

The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.

MicroPort CardioFlow’s Alwide® Plus Balloon Catheter Gains CE Mark Approval

MicroPort CardioFlow Medtech Corp. announced that its Alwide® Plus balloon catheter has received CE Mark approval, signifying compliance with European health and safety standards. This approval not only enhances the company’s product offerings in the European market but also supports its overseas revenue growth and commercialization efforts for other products like the VitaFlow Liberty® system. The approval highlights the company’s strong technological capabilities and strategic positioning in the global high-end medical device market.

MicroPort CardioFlow Reports Major Reduction in 2025 Net Loss

MicroPort CardioFlow Medtech Corp. announced a significant reduction in net loss for the first half of 2025, expecting a decrease of no less than 83% compared to the same period in 2024. This improvement is attributed to increased overseas sales, successful commercialization of new products in Europe and China, enhanced operational efficiency, and financial gains from an associate company’s financing round.